Unveiling skeletal fragility in patients diagnosed with MGUS: No longer a condition of undetermined significance?

Journal of Bone and Mineral Research

Volumn 29, Issue 12, 2014, Pages 2529-2533

  Drake, Matthew T ^a  

^a MAYO CLINIC   (United States)

Author keywords

DXA; Fracture; HRPQCT; MGUS; Osteoporosis

Indexed keywords

DICKKOPF 1 PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; CCL3 PROTEIN, HUMAN; DKK1 PROTEIN, HUMAN; SIGNAL PEPTIDE;

BIOMECHANICS; BONE DISEASE; BONE FRAGILITY; BONE STRENGTH; DISEASE COURSE; DISEASE SEVERITY; HUMAN; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; REVIEW; ADULT; AGED; BLOOD; COMPLICATION; FEMALE; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; OSTEOPOROSIS;

ADULT; AGED; CHEMOKINE CCL3; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; OSTEOPOROSIS;

EID: 84918532142     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2387     Document Type: Review

References (67)

1. Office of the Surgeon General. The 2004 Surgeon General's report on bone health and osteoporosis. Rockville, MD: Office of the Surgeon General US; 2004.
2. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22(3): 465-75.
3. Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ 3rd. The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: An update in NHANES 2005-2008. Osteoporos Int. 2012;23(3): 811-20.
4. Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012;23(9): 2239-56.
5. Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008;19(4): 449-58.
6. Sattui SE, Saag KG. Fracture mortality: Associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol. 2014;10(10): 592-602.
7. Kanis JA, Hans D, Cooper C, et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int. 2011;22(9): 2395-411.
8. Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6): 1121-7.
9. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol. 2003;121(5): 749-57.
10. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2): 71-96.
11. Roodman GD. Pathogenesis of myeloma bone disease. Leukemia. 2009;23(3): 435-41.
12. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Hematol Oncol Clin N Am. 2007;21(6): 1093-113, ix.
13. Cohen HJ, Crawford J, Rao MK, Pieper CF, Currie MS. Racial differences in the prevalence of monoclonal gammopathy in a communitybased sample of the elderly. Am J Med. 1998;104(5): 439-44.
14. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006;107(3): 904-6.
15. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13): 1362-9.
16. Wadhera RK, Rajkumar SV. Prevalence of monoclonal gammopathy of undetermined significance: A systematic review. Mayo Clin Proc. 2010;85(10): 933-42.
17. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8): 564-9.
18. Therneau TM, Kyle RA, Melton LJ 3rd, et al. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc. 2012;87(11): 1071-9.
19. Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med. 1978;64(5): 814-26.
20. Melton LJ 3rd, Rajkumar SV, Khosla S, Achenbach SJ, Oberg AL, Kyle RA. Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res. 2004;19(1): 25-30.
21. Kristinsson SY, Tang M, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: A population- based study. Blood. 2010;116(15): 2651-5.
22. Gregersen H, Jensen P, Gislum M, Jorgensen B, Sorensen HT, Norgaard M. Fracture risk in patients with monoclonal gammopathy of undetermined significance. Br J Haematol. 2006;135(1): 62-7.
23. Golombick T, Diamond T. Prevalence of monoclonal gammopathy of undetermined significance/myeloma in patients with acute osteoporotic vertebral fractures. Acta Haematol. 2008;120(2): 87-90.
24. Pepe J, Petrucci MT, Nofroni I, et al. Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance. Br J Haematol. 2006;134(5): 485-90.
25. Bida JP, Kyle RA, Therneau TM, et al. Disease associations with monoclonal gammopathy of undetermined significance: A population- based study of 17, 398 patients. Mayo Clin Proc. 2009;84(8): 685-93.
26. Edwards BJ, Langman CB, Bunta AD, Vicuna M, Favus M. Secondary contributors to bone loss in osteoporosis related hip fractures. Osteoporos Int. 2008;19(7): 991-9.
27. Drake MT. Osteoporosis and cancer. Curr Osteoporos Rep. 2013; 11(3): 163-70.
28. Abrahamsen B, Andersen I, Christensen SS, Skov Madsen J, Brixen K. Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: Retrospective, cross sectional study. BMJ. 2005;330(7495): 818.
29. Blade J, Clinical practice. Monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;355(26): 2765-270.
30. Berenson JR, Anderson KC, Audell RA, et al. Monoclonal gammopathy of undetermined significance: A consensus statement. Br J Haematol. 2010;150(1): 28-38.
31. Minisola S, Pepe J, Romagnoli E. Monoclonal gammopathy of undetermined significance. N Engl J Med. 2007;356(21): 2223-4; author reply 2223-4.
32. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25(17): 2464-72.
33. Anderson KC, Alsina M, Bensinger W, et al. NCCN clinical practice guidelines in oncology: Multiple myeloma. J Natl Compr Canc Netw. 2009;7(9): 908-42.
34. Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006;81(8): 1047-53.
35. Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol. 2009;20(8): 1303-17.
36. Terpos E, Morgan G, Dimopoulos MA, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013;31(18): 2347-57.
37. Raje N, Roodman GD. Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res. 2011;17(6): 1278-86.
38. Drake MT. Bone disease in multiple myeloma. Oncology. 2009;23(14 Suppl 5): 28-32.
39. Melton LJ 3rd, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV. Fracture risk with multiple myeloma: A population-based study. J Bone Miner Res. 2005;20(3): 487-93.
40. Bataille R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest. 1991;88(1): 62-6.
41. Minter AR, Simpson H, Weiss BM, Landgren O. Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: Pathogenesis, interventions, and future opportunities. Semin Hematol. 2011;48(1): 55-65.
42. Fowler JA, Edwards CM, Croucher PI. Tumor-host cell interactions in the bone disease of myeloma. Bone. 2011;48(1): 121-8.
43. Sezer O, Heider U, Jakob C, et al. Immunocytochemistry reveals RANKL expression of myeloma cells. Blood. 2002;99(12): 4646-7; author reply 4647.
44. Oba Y, Lee JW, Ehrlich LA, et al. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol. 2005;33(3): 272-28.
45. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349(26): 2483-94.
46. Oshima T, Abe M, Asano J, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood. 2005; 106(9): 3160-5.
47. Giuliani N, Morandi F, Tagliaferri S, et al. Production of Wnt inhibitors by myeloma cells: Potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res. 2007;67(16): 7665-74.
48. Kristensen IB, Christensen JH, Lyng MB, et al. Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: Only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease. Leuk Lymphoma. 2014;55(4): 911-9.
49. Colucci S, Brunetti G, Oranger A, et al. Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J. 2011;1(6): E27.
50. Terpos E, Christoulas D, Katodritou E, et al. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy. Int J Cancer. 2012;131(6): 1466-71.
51. Garderet L, Mazurier C, Chapel A, et al. Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk Lymphoma. 2007;48(10): 2032-41.
52. Corre J, Mahtouk K, AttalM, et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia. 2007;21(5): 1079-88.
53. Arnulf B, Lecourt S, Soulier J, et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia. 2007;21(1): 158-63.
54. Gregory CA. More progress defining the crosstalk between multiple myeloma and mesenchymal stem cells of the bone marrow. Leuk Lymphoma. 2007;48(10): 1896-7.
55. Bataille R, Chappard D, Basle MF. Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: A prospective study of 87 bone biopsies. Blood. 1996;87(11): 4762-9.
56. Giuliani N, Ferretti M, Bolzoni M, et al. Increased osteocyte death in multiple myeloma patients: Role in myeloma-induced osteoclast formation. Leukemia. 2012;26(6): 1391-401.
57. Roussou M, Tasidou A, Dimopoulos MA, et al. Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia. 2009;23(11): 2177-81.
58. Ng AC, Khosla S, Charatcharoenwitthaya N, et al. Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1alpha levels in patients with MGUS. Blood. 2011;118(25): 6529-34.
59. Terpos E, Dimopoulos MA, Sezer O, et al. The use of biochemical markers of bone remodeling in multiple myeloma: A report of the International Myeloma Working Group. Leukemia. 2010;24(10): 1700-12.
60. Diamond T, Levy S, Smith A, Day P, Manoharan A. Non-invasive markers of bone turnover and plasma cytokines differ in osteoporotic patients with multiple myeloma and monoclonal gammopathies of undetermined significance. Intern Med J. 2001;31(5): 272-8.
61. Pecherstorfer M, Seibel MJ, Woitge HW, et al. Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: Quantification by urinary pyridinium cross-links of collagen. Blood. 1997;90(9): 3743-50.
62. Laroche M, Attal M, Dromer C. Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma. Clin Rheumatol. 1996;15(4): 347-52.
63. Farr JN, Zhang W, Kumar SK, et al. Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance. Blood. 2014;123(5): 647-9.
64. Seeman E, Delmas PD. Bone quality-Thematerial and structural basis of bone strength and fragility. N Engl J Med. 2006;354(21): 2250-61.
65. Bousson V, Bergot C, Sutter B, Levitz P, Cortet B. Trabecular bone score (TBS): Available knowledge, clinical relevance, and future prospects. Osteoporos Int. 2012;23(5): 1489-501.
66. Melton LJ III, Rajkumar SV, Khosla S, Achenbach SJ, Oberg AL, Kyle RA. Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res. 2004;19: 25-30.
67. Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): Novel biological insights and development of early treatment strategies. Blood. 2011;117(21): 5573-81.